ERBB2 and neoplasm: Progression-free survival on first line therapy was longer for patients whose tumour had at least one actionable alterations vs those who did not (p =.029, Fig. 3A), but this difference was no longer significant when patients with HER2+ tumors were excluded (Fig. 3B).